Tag: starts
-
Before School Starts, Train Everyone’s Brains for Allergies and Asthma – Newswise (press release)
Newswise (press release) Before School Starts, Train Everyone's Brains for Allergies and AsthmaNewswise (press release)“More than 10 million kids under age 18 have asthma, and one in four suffer from respiratory allergies,” said allergist James Sublett, MD, FACAAI, president of the American College of Allergy, Asthma and Immunology (ACAAI). “Many kids with asthma and …Benjamin Moore…
-
The battle against asthma starts at home – The Detroit News
The Detroit News The battle against asthma starts at homeThe Detroit NewsA recent story in The Detroit News pointed to the extent of asthma in Detroit (“Health providers target Detroit's asthma woes,” Dec. 4). Karen Bouffard's report emphasized education and medical interventions to treat and control asthma. Both are important. View full post on asthma…
-
AstraZeneca starts Phase III program for asthma drug tralokinumab – Pharmaceutical Business Review
AstraZeneca starts Phase III program for asthma drug tralokinumabPharmaceutical Business ReviewAstraZeneca has started the Phase III program for an investigational human monoclonal antibody tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by the company's global biologics research and … View full post on asthma – Google News
-
AstraZeneca starts final-stage tests on severe asthma drug – Reuters
Reuters UK AstraZeneca starts final-stage tests on severe asthma drugReutersSeveral firms are racing to develop injectable biotech asthma drugs for patients with severe disease who do not respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion a year. (Reporting by Ben Hirschler, Editing …AstraZeneca Starts Phase III Trial…
-
Dynavax starts Phase I trial of asthma treatment – San Francisco Business Times (blog)
Dynavax starts Phase I trial of asthma treatmentSan Francisco Business Times (blog)The Berkeley company (NASDAQ: DVAX) will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo. If all goes…
-
Asthma education series ‘Breathe Well, Live Well’ starts April 1 – Norwich Bulletin
Asthma education series 'Breathe Well, Live Well' starts April 1Norwich BulletinA curriculum by the American Lung Association, “Breathe Well, Live Well” teaches participants self-management skills to keep their asthma under control, have fewer symptoms and gain a better quality of life. Classes will be taught by Ray Tarvin … View full post on asthma –…
-
Invion starts second phase trial for asthma treatment – MENAFN.COM
MENAFN.COM Invion starts second phase trial for asthma treatmentMENAFN.COM(MENAFN – ProactiveInvestors – Australia) Invion (ASX: IVX) has initiated the phase II "NIMA" clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and …and more » View full post on asthma…
-
Invion starts second phase trial for asthma treatment – Proactive Investors Australia
Proactive Investors Australia Invion starts second phase trial for asthma treatmentProactive Investors AustraliaInvion (ASX: IVX) has initiated the phase II “NIMA” clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and Infectious Diseases through a cooperative … View full…
-
GlaxoSmithKline starts final-stage tests on severe asthma drug – Fox News
GlaxoSmithKline starts final-stage tests on severe asthma drugFox NewsSevere refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. Print; Email; Share; Comments; Recommend …GSK Begins Phase lll Program…
-
GSK starts final-stage tests on severe asthma drug – Reuters
GSK starts final-stage tests on severe asthma drugReutersSevere refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. (Reporting by Ben Hirschler). Health …GSK Begins Phase lll Program for…